Cannabidiol provides viable treatment opportunity for multipleneurological pathologies of autism spectrum disorder Bin Gu Global Drugs and Therapeutics, Review article, 2017, 2, 6, 1-4 doi: 10.15761/GDT.1000134 Abstract Autism spectrum disorder (ASD)is a heterogeneous neurodevelopmental disorderaffecting over 1% of the general population. While it is well established that ASD stems from a combination of genetic and environmental factors, there are no defined mechanisms of pathogenesis, rendering curative therapy very difficult to establish. No effective therapy exists for ASD, presenting an urgent clinical need for better control of common core pathologies of ASD regardless of its etiology. Cannabidiol (CBD), a major phytocannabinoid constituent of the cannabis plant, is [...]
Lire la suiteAmende forfaitaire étendue au délit d’usage de stupéfiants : Une nouvelle étape franchie dans la politique régressive en matière de drogues Communiqué de presse du 22 mars 2019 Le Conseil constitutionnel a rendu hier sa décision sur la loi de programmation 2018-2022 et de réforme pour la justice. Elle valide l’extension de l’amende forfaitaire délictuelle - un objet pénal non identifié qui dissuade le citoyen de faire valoir ses droits - à l’usage de stupéfiants. Le délit d’usage de stupéfiants pourra ainsi désormais faire l’objet d’une amende forfaitaire de 200 €. Le Conseil constitutionnel, au terme d’une longue motivation, a assorti [...]
Lire la suiteCommentaires (Dr Christian Sueur) sur l'article : The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI) : a multicentre case-control study Marta Di Forti, et al., and the EU-GEI WP2 Group* www.thelancet.com/psychiatry, 2019 "Une nouvelle étude montre que les personnes qui consomment quotidiennement du cannabis fortement dosé en THC pourraient avoir cinq fois plus de risque de faire un épisode de psychose que celles qui n’en ont jamais pris. La consommation quotidienne de variétés fortes de cannabis serait responsable de cinq nouveaux cas de troubles mentaux sur dix, de type psychose, à Amsterdam et de trois [...]
Lire la suiteThe contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI) : a multicentre case-control study Marta Di Forti, Diego Quattrone, Tom P Freeman, Giada Tripoli, Charlotte Gayer-Anderson, Harriet Quigley, Victoria Rodriguez, Hannah E Jongsma, Laura Ferraro, Caterina La Cascia, Daniele La Barbera, Ilaria Tarricone, Domenico Berardi, Andrei Szöke, Celso Arango, Andrea Tortelli, Eva Velthorst, Miguel Bernardo, Cristina Marta Del-Ben, Paulo Rossi Menezes, Jean-Paul Selten, Peter B Jones, James B Kirkbride, Bart PF Rutten, Lieuwe de Haan, Pak C Sham, Jim van Os, Cathryn M Lewis, Michael Lynskey, Craig Morgan, Robin M Murray, and the EU-GEI WP2 [...]
Lire la suiteReview article : The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroinflammatory diseases Valerio Chiurchiù, Mario van der Stelt, Diego Centonzed, Mauro Maccarrone, Progress in Neurobiology, 2018, 160 , 82–100 © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). A B S T R A C T Multiple sclerosis is the most common inflammatory demyelinating disease of the central nervous system, caused by an autoimmune response against myelin that eventually leads to progressive neurodegeneration and disability. Although the knowledge on its underlying neurobiological mechanisms has considerably improved, there is a [...]
Lire la suiteRegulatory Barriers to Research on Cannabis and Cannabinoids : A Proposed Path Forward Daniele Piomelli, Robert Solomon, Donald Abrams, Agnes Balla, Igor Grant, Thomas Marcotte, and John Yoder Cannabis and Cannabinoid Research, Volume 4, Number 1, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2019.0010 After a century of criminalization, the United States and other industrialized countries are experiencing a dramatic shift in their social and legal attitudes toward cannabis. As of January 2019, 10 states (including California) and the District of Columbia have legalized the plant and its products for both medical and adult recreational use, whereas 24 other states have decriminalized its use as medicine.1 [...]
Lire la suiteDemystifying Cannabis Daniele Piomelli, Cannabis and Cannabinoid Research, Volume 4, Number 1, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2019.29012.edi Every new book by Malcolm Gladwell goes, by default, straight to the top of my reading list. In the unlikely event that you are not familiar with the work of this Canadian author, make time to read The Tipping Point (Little, Brown and Co., 2000) or Outliers (Little, Brown and Co., 2008), and you will see why. Not only Gladwell is remarkably well informed and clear, as one would expect from an accomplished writer and public speaker, but he also has an unusual knack for uncovering [...]
Lire la suiteTreatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature Nicole Tartaglia, Marcel Bonn-Miller, and Randi Hagerman Cannabis and Cannabinoid Research, 2019, 4, 1 https://doi.org/10.1089/can.2018.0053 Abstract Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those who suffer from FXS. The objective of this study was to provide a brief narrative review of recent literature on endocannabinoids and FXS and [...]
Lire la suiteMedicinal Use of Synthetic Cannabinoids—a Mini Review P. Muralidhar Reddy, Nancy Maurya & Bharath Kumar Velmurugan Current Pharmacology Reports, 2019 https://doi.org/10.1007/s40495-018-0165-y Abstract Purpose of Review : This review gives an overview of the medicinal uses of synthetic cannabinoids and other related aspects on the basis of recent as well as earlier studies that the authors considered relevant to the context and scope of the review. Recent Findings Synthetic cannabinoids are laboratory synthesized products eliciting effects way more than their natural counterparts. These compounds are more potent in generating intoxicating effects and are also difficult to be detected in conventional screening tests. Their clinical side effects are also more pronounced than [...]
Lire la suiteLong-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US Tristan T. Sands, Shahryar Rahdari, Michael S. Oldham, Eduardo Caminha Nunes, Nicole Tilton & Maria Roberta Cilio CNS Drugs, 2018 DOI : 10.1007/s40263-018-0589-2 Abstract Background : Purified cannabidiol is a new antiepileptic drug that has recently been approved for use in patients with Lennox–Gastaut and Dravet syndromes, but most published studies have not extended beyond 12–16 weeks. Objective : The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy. Methods : Patients aged 1–17 years with refractory epilepsy were enrolled in an open-label [...]
Lire la suite